Kidney cancer patients can use Goopatient to record test results, symptoms, side effects from chemotherapy, targeted therapy, or immunotherapy, as well as track changes in their well-being between doctor visits. For example, patients can create #hashtags for pain levels, fatigue, appetite changes, or medication responses to monitor progress and share accurate information with their oncologist. Goopatient also allows patients to store information about prescribed medications, scheduled examinations, surgeries, and consultations, as well as receive reminders for medications and clinic appointments. This is especially useful for people undergoing long-term kidney cancer treatment, when it's crucial to stay on top of details.
You can also add to your health journal encourading news about advances in the renal cancer management. Here are some of them:
New drug shows effectiveness against renal cancer
A team of scientists from the Yale University School of Medicine, led by David Brown, in 2026 conducted clinical trials of a new immunotherapeutic drug that reaches immune cells and inhibits the enzyme HPK1, one of the inhibitory mechanisms of T cells. Preclinical experiments have shown that deactivating HPK1 powerfully enhances the immune response against cancer. The trial involved 22 patients with solid tumors, but the most pronounced effect was observed in patients with metastatic clear cell renal cell carcinoma. One patient achieved sustained remission, while in others, tumors significantly shrank and remained stable. For example, in one participant, the tumor did not grow for more than two years after treatment. Now the scientists need to determine the optimal dosage of the drug and confirm the results in a larger sample.
New cancer vaccine makes immunotherapy effective for 75% of cancer patients
Cancer immunotherapy is highly effective against melanoma, squamous cell skin cancer, lung, kidney, and liver tumors, but it only works in 20% of cases. German scientists from the University of Konstanz in 2021 developed a vaccine that can make immunotherapy 75% effective. The vaccine is based on the immunostimulant riboxim, already approved for use in humans. Riboxim induces a T-cell response, which is essential for the effectiveness of immune checkpoint blocking drugs, the scientists explain. The team has now completed mouse trials and launched the pilot phase of clinical trials.